Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
Sarepta Therapeutics (NASDAQ:SRPT) has announced the recipients of its 7th Annual Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year. 25 scholarships have been awarded, including 20 to individuals living with Duchenne muscular dystrophy and 5 to siblings of individuals with Duchenne. Each recipient will receive up to $5,000.
The program, created in 2018, recognizes exceptional individuals pursuing post-secondary education. Recipients are chosen by an independent committee based on community involvement, academic achievements, and personal essays. Since its inception, Sarepta has awarded nearly 140 scholarships through the Route 79 program.
Sarepta Therapeutics (NASDAQ:SRPT) ha annunciato i destinatari del suo 7° Annuale Route 79, il Programma di Borse di Studio Duchenne per l'anno accademico 2024-2025. Sono state assegnate 25 borse di studio, di cui 20 a persone affette da distrofia muscolare di Duchenne e 5 a fratelli di individui con Duchenne. Ogni destinatario riceverà fino a $5.000.
Il programma, creato nel 2018, riconosce individui eccezionali che perseguono l'istruzione post-secondaria. I destinatari sono scelti da un comitato indipendente in base al coinvolgimento nella comunità, ai risultati accademici e ai saggi personali. Fin dalla sua creazione, Sarepta ha assegnato quasi 140 borse di studio attraverso il programma Route 79.
Sarepta Therapeutics (NASDAQ:SRPT) ha anunciado los beneficiarios de su 7ª Ruta Anual 79, el Programa de Becas Duchenne para el año académico 2024-2025. Se han otorgado 25 becas, incluyendo 20 a personas que viven con distrofia muscular de Duchenne y 5 a hermanos de individuos con Duchenne. Cada beneficiario recibirá hasta $5,000.
El programa, creado en 2018, reconoce a individuos excepcionales que persiguen una educación postsecundaria. Los beneficiarios son seleccionados por un comité independiente basado en la participación comunitaria, los logros académicos y los ensayos personales. Desde su inicio, Sarepta ha otorgado casi 140 becas a través del programa Ruta 79.
Sarepta Therapeutics (NASDAQ:SRPT)는 2024-2025 학년도에 대한 제7회 연례 Route 79, Duchenne 장학금 프로그램 수혜자를 발표했습니다. 25개의 장학금이 수여되었으며, 그 중 20개는 듀셴 근육디스트로피 환자에게, 5개는 듀셴 환자의 형제자매에게 수여됩니다. 각 수혜자는 최대 $5,000를 받게 됩니다.
2018년에 만들어진 이 프로그램은 고등 교육을 추구하는 뛰어난 개인을 인정합니다. 수혜자는 지역 사회 참여, 학업 성취 및 개인 에세이를 기반으로 독립 커미티에 의해 선정됩니다. 설립 이후 Sarepta는 Route 79 프로그램을 통해 거의 140개의 장학금을 수여해왔습니다.
Sarepta Therapeutics (NASDAQ:SRPT) a annoncé les bénéficiaires de son 7ème Programme de Bourses Duchenne, Route 79, pour l'année académique 2024-2025. 25 bourses ont été attribuées, incluant 20 à des personnes vivant avec la dystrophie musculaire de Duchenne et 5 à des frères et sœurs d’individus atteints de Duchenne. Chaque bénéficiaire recevra jusqu'à 5 000 $.
Ce programme, créé en 2018, reconnaît des individus exceptionnels poursuivant des études supérieures. Les bénéficiaires sont choisis par un comité indépendant sur la base de leur engagement communautaire, de leurs réalisations académiques et de leurs essais personnels. Depuis sa création, Sarepta a attribué près de 140 bourses à travers le programme Route 79.
Sarepta Therapeutics (NASDAQ:SRPT) hat die Empfänger seines 7. jährlichen Route 79, des Duchenne-Stipendienprogramms für das akademische Jahr 2024-2025 bekannt gegeben. Es wurden 25 Stipendien vergeben, darunter 20 an Personen mit Duchenne-Muskeldystrophie und 5 an Geschwister von Personen mit Duchenne. Jeder Empfänger erhält bis zu 5.000 $.
Das Programm, das 2018 ins Leben gerufen wurde, erkennt außergewöhnliche Personen an, die eine höhere Ausbildung anstreben. Die Empfänger werden von einem unabhängigen Ausschuss aufgrund ihres Engagements in der Gemeinschaft, ihrer akademischen Leistungen und persönlichen Essays ausgewählt. Seit seiner Gründung hat Sarepta durch das Route 79-Programm fast 140 Stipendien vergeben.
- Sarepta Therapeutics awarded 25 scholarships of up to $5,000 each for the 2024-2025 academic year
- The company has awarded nearly 140 scholarships through the Route 79 program since 2018
- The program expanded in 2022 to include siblings of individuals with Duchenne
- None.
– Recipients include 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne
“On behalf of Sarepta and the selection committee, we are thrilled to announce the recipients of Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year. From small private colleges to some of the largest research universities in the world, this class of recipients were impressive for their academic success, profound curiosity, commitment to learning and fierce determination,” said Diane Berry, Ph.D., executive vice president and Chief Global Policy & Advocacy Officer, Sarepta. “Over the past seven years, Sarepta has awarded nearly 140 scholarships through the Route 79 program. We are honored to support the growth of these young adults as they begin the next chapter of their academic journey.”
The Route 79 program was created in 2018 to recognize exceptional individuals living with Duchenne as they pursue their post-secondary education. In 2022, Sarepta expanded the program to include siblings of individuals with Duchenne in recognition of the impact that a diagnosis of Duchenne may have on the entire family. Recipients of the scholarship are chosen by an independent selection committee composed of Duchenne community members, who consider each applicant’s community involvement, academic achievements, and personal essay. In addition to application review by the independent committee, submissions are de-identified for the selection committee with no indication of whether the candidate has received, or plans to receive, a Sarepta therapy.
2024-2025 Route 79 Scholarship Recipients
-
John “Jack” Becker, Embry-Riddle Aeronautical University,
Daytona Beach - Jacob Colby, The Evergreen State College
- Kyle Cox, Texas A&M University
-
Bradon Coy, University of
Florida -
John Herzfeld, Arizona State University,
Downtown Phoenix - Declan Hickey, Curry College
- Elliott Johnson, Lebanon Valley College
- Henry Johnson, Temple University
-
Ryan Lugo, State University of
New York atNew Paltz - John McConnell, Boise State University
- Josh Pflueger, Texas Christian University
- Ryan Schultz, Rowan University
- Jasdeep Singh, Cleveland Institute of Art
-
Parker Strobeck,
North Arkansas College - Robert Sullivan, John Carroll University
-
William Sun, University of
California , Davis - Braden Van Eperen, Union College
- Connor Vassigh, Lone Star College System
- Max Vertin, Hastings College
-
Jack Wolf, University of
Dayton
2024-2025 Route 79 Sibling Scholarship Recipients
-
Abraham Dreher,
Bennington College -
Addison Griffin,
Auburn University -
Mateo Ramirez Laverde Guzman, University of
North Carolina atChapel Hill -
Alexis Udell, University of
Wisconsin -Madison - Austin Vassigh, Texas A&M University
About Route 79, The Duchenne Scholarship Program
The Route 79 program is designed to help students living with Duchenne and siblings of individuals living with Duchenne pursue their post-secondary educational goals. Scholarship recipients are chosen by an independent committee of Duchenne community members based on an applicant’s community involvement, personal essay, and recommendation letter. The underlying cause of Duchenne is a difference in the gene coding for dystrophin. Dystrophin is an essential protein that plays a pivotal role in muscle structure, function and preservation. The numerical significance of the scholarship’s name, Route 79, ties to the 79 exons of the dystrophin gene. For more information, visit sarepta.com/route79.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905023581/en/
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
FAQ
How many scholarships did Sarepta Therapeutics award for the 2024-2025 academic year through the Route 79 program?
What is the value of each scholarship awarded by Sarepta Therapeutics (SRPT) in the Route 79 program?
When did Sarepta Therapeutics (SRPT) create the Route 79 Duchenne Scholarship Program?
How many scholarships has Sarepta Therapeutics (SRPT) awarded through the Route 79 program since its inception?
